The Effects and Mechanism of SGLT2 Inhibitors in Stage B of Heart Failure With Hypertension
Heart Failure, Hypertension, Left Ventricle Remodeling
About this trial
This is an interventional treatment trial for Heart Failure
Eligibility Criteria
Inclusion Criteria: • Meeting all the following criteria: Aged 40 and above. Hypertensive patients currently taking at least one antihypertensive medication as recommended by guidelines, and blood pressure is within the target range (<140/90 mmHg). B-type natriuretic peptide (BNP) levels between 35-280 pg/mL or N- terminal pro-B-type natriuretic peptide (NT-pro BNP) levels between 125-1000 pg/mL in the past 6 months. Left atrial volume index measured by echocardiography exceeding 34 mL/m² in the past 6 months. Signing an informed consent form. Exclusion Criteria: • Exclusion criteria include any of the following conditions: History of diabetes. History of heart failure. History of coronary artery disease. Left ventricular systolic dysfunction, defined as LVEF < 50%. Systolic blood pressure < 100 mmHg. Persistent atrial fibrillation. Severe valvular heart disease. Severe obstructive disease of the left ventricular outflow tract, including aortic valve stenosis. Genitourinary tract infection. Chronic kidney disease or estimated Glomerular Filtration Rate (eGFR) < 45 ml/min/1.73m². Alanine aminotransferase or aspartate aminotransferase levels > 3 times the upper limit of normal. Contraindications to taking SGLT2 inhibitors. Currently taking SGLT2 inhibitors, SGLT-1/2 inhibitors, or other antihyperglycemic medications (including metformin, glucagon-like peptide-1 receptor agonists, etc.). Pregnancy or planning pregnant, or currently breastfeeding. Malignant tumors or other severe illnesses with a life expectancy of less than 3 years. History of alcohol abuse or substance abuse within the past year. Mental disorders or communication barriers, cognitive impairments, or other severe illnesses that may affect participation in the study. Participation in or currently participating in other clinical trials within the last 3 months. Known poor compliance with study follow-up or study drug. Any condition or contraindication that makes a person intolerant to magnetic resonance imaging (MRI) or contraindicates MRI examination, such as the presence of implanted intracranial aneurysm clips, cardiac pacemakers or defibrillators, insulin pumps, etc.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Empagliflozin
Placebo